Who
Karen A. Dawes
Director
Company insider
Files Form 4 as: Director, Barinthus Biotherapeutics; Director, Repligen; Director, Assertio Therapeutics; Chairperson of the Board, Pdl Biopharma.
In numbers
- Trades disclosed
- 235
- Buys
- 9
- Sells
- 28
- Bought
- $129K
- Sold
- $19.0M
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 14 Jun 2006
- Last trade
- 9 Sep 2026
- Last filed
- 9 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Sep 2026filed 9 Sep 2026 | Barinthus BiotherapeuticsBiotechnology | SEC FORM 4 Code D | —1,700 | filing |
| 9 Sep 2026filed 9 Sep 2026 | Barinthus Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —34,328 at $0.00 | filing |
| 9 Sep 2026filed 9 Sep 2026 | Barinthus Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —18,604 at $0.00 | filing |
| 9 Sep 2026filed 9 Sep 2026 | Barinthus Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —34,328 at $0.00 | filing |
| 9 Sep 2026filed 9 Sep 2026 | Barinthus Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —18,604 at $0.00 | filing |
| 9 Sep 2026filed 9 Sep 2026 | Barinthus Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —19,197 at $0.00 | filing |
| 9 Sep 2026filed 9 Sep 2026 | Barinthus Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —19,516 at $0.00 | filing |
| 9 Sep 2026filed 9 Sep 2026 | Barinthus Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —20,174 at $0.00 | filing |
| 9 Sep 2026filed 9 Sep 2026 | Barinthus Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —19,197 at $0.00 | filing |
| 9 Sep 2026filed 9 Sep 2026 | Barinthus Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —19,516 at $0.00 | filing |
| 9 Sep 2026filed 9 Sep 2026 | Barinthus Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —20,174 at $0.00 | filing |
| 9 Sep 2026filed 9 Sep 2026 | Barinthus BiotherapeuticsBiotechnology | SEC FORM 4 Code D | —1,700 | filing |
| 14 May 2026filed 18 May 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Code A | —995 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | RGEN Repligenoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,239 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | RGEN Repligenoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,239 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Code A | —995 at $0.00 | filing |
| 17 Dec 2025filed 18 Dec 2025 | RGEN RepligenBiotechnology | SEC FORM 4 Sold | $44K275 at $161.00 | filing |
| 10 Jun 2025filed 11 Jun 2025 | Barinthus Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,174 at $0.00 | filing |
| 15 May 2025filed 19 May 2025 | RGEN Repligenoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,800 at $0.00 | filing |
| 15 May 2025filed 19 May 2025 | RGEN RepligenBiotechnology | SEC FORM 4 Code A | —973 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.